Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Scholar Rock Holding Corp logo
    SRRK

    Scholar Rock Holding Corp

    MaveScore 22 Low model confidence
    Last Price US$56.71 As of Jul 10, 2026
    Market Cap US$6.8b Company size context
    7D Performance 3.33% Past 7 days
    1Y Performance 48.85% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    102 days old

    Market price date

    Jul 10, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 22 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    6/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    6/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    0/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    10/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Scholar Rock Holding Corp Overview

    Industry: Biotechnology

    Sector: Healthcare

    Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent Read More

    Scholar Rock Holding Corp is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Scholar Rock Holding Corp

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    EPS was $0.83 (reported).

    EPS $0.83 reported
    Net loss -$105.5M reported
    R&D expense $51.8M reported
    G&A expense $50.2M reported

    What changed

    • EPS reported to $0.83.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 07, 2026 SEC filing 8-K May 07, 2026 Earnings material Earnings release May 07, 2026 SEC filing 10-K Mar 03, 2026 SEC filing FORM 8-K/A Mar 03, 2026 SEC filing 8-K Mar 03, 2026 Earnings release EXHIBIT 99.1 Mar 03, 2026 Earnings release Earnings release Mar 03, 2026 SEC filing 8-K Jan 12, 2026 SEC filing 8-K Nov 14, 2025 Earnings release Earnings release Nov 14, 2025

    Recent News



    Scholar Rock stock price target raised to $50 from $45 at BMO Capital
    11 minutes ago
    Scholar Rock (NASDAQ:SRRK) Issues Earnings Results
    57 minutes ago
    SRRK stock prediction for this week - July 2025 Short Interest & Growth Focused Entry Reports
    2 hours ago

    Earnings Per Share

    Score 2.00/5
    Scholar Rock Holding Corp earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score -0.01/5
    Scholar Rock Holding Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Scholar Rock... SRRK US$6.8b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Net Margin

    Score 0.92/5
    Scholar Rock Holding Corp olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Scholar Rock... SRRK US$6.8b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.75/5
    Scholar Rock Holding Corp attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Scholar Rock... SRRK US$6.8b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Scholar Rock Holding Corp logo

    Scholar Rock Holding Corp

    US$56.71

    US$6.8b

    3.33%

    48.85%